Researchers at the University of Hong Kong have unveiled a promising new approach to treating one of blood cancer’s most difficult variants. The QUIZOM combination therapy—pairing Quizartinib, an FDA-approved FLT3 inhibitor, with Omacetaxine Mepesuccinate—has demonstrated an 83% complete remission rate in patients with FLT3-mutated acute myeloid leukemia.
FLT3 mutations, present in approximately 30% of acute myeloid leukemia cases, are associated with aggressive disease progression and resistance to conventional therapies. The dual-mechanism approach not only suppresses cancer cell growth but also activates the patient’s immune system to target remaining malignant cells.
The breakthrough is particularly significant because it extends the critical window for bone marrow transplantation, a life-saving procedure that many high-risk patients previously had limited access to. This advancement addresses a substantial gap in current treatment protocols where single-agent therapies frequently fail to achieve durable remissions.
Read the full article on GMJ Newsroom.
Was this article helpful?
